Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Upadacitinib in Adult Axial Spondyloarthritis
2019-003229-12Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) (4 arms), sponsored by AbbVie Inc. Started Nov 2019; status: active.
02
Drugs
upadacitinib
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2019-003229-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003229-12.